Ingredient and route are separate decisions
An ingredient tells you what a product contains. A route tells you how it is administered. Write both down before comparing offers: oral NR, oral NMN, injected NAD+ and intravenous NAD+ are different descriptions. A brand can sell several products, so its name alone is not enough to identify the option you are evaluating.
For each listing, also record whether it is presented as a supplement, a compounded prescription or something else. If the product page does not make that clear, leave the field unresolved and ask. A clinician consultation, a pharmacy name and a familiar wellness brand do not answer the same question as product approval.
What compounding does and does not establish
FDA explains that compounded drugs are not FDA-approved: the agency does not verify their safety, effectiveness or quality before marketing. Compounding can address a patient's needs when an approved drug is not appropriate. That purpose should not be mistaken for FDA approval of a particular compounded NAD product. [1]
FDA has separately warned about ingredients unsuitable for sterile compounding. Its NAD+ notice describes adverse-event reports including severe chills, shaking, vomiting and fatigue, sometimes requiring medical treatment; the reactions were consistent with excessive endotoxins. The notice is a specific quality warning, not a comparison showing that one wellness brand is safer than another. [2]
Ask questions that match the format
For an injectable offer, request the dispensing pharmacy's identity, the actual product label and written storage information. Ask who handles a damaged shipment, how to reach the clinical team and what support is available if a problem occurs. Those are practical questions for the provider; this guide cannot verify an individual batch or replace its instructions.
For an in-person service, clarify the location, expected visit duration, screening process, monitoring and what happens if a visit needs to stop early. For a subscription, clarify what a renewal includes and whether unused appointments carry over. A low per-visit headline can conceal a larger required purchase.
For an oral product, start with the label: ingredient, serving information, quantity and other ingredients. Compare the same product and purchase type across sellers. “NAD support” on the front of a bottle is not enough to tell whether the active ingredient is NAD+, NR or NMN.
Convenience is not clinical equivalence
It is reasonable to compare travel, time, needles, storage and recurring expense. Those practical preferences do not establish that one route produces better health outcomes. An oral precursor trial does not directly test an injected NAD product, and a faster appointment is not proof of a greater benefit. Keep the practical comparison beside the evidence comparison rather than blending them together.
Our format explorer filters the directory by the exact ingredient-route pair. It may return no listings, which simply means no matching listing is in this directory. It is not a judgment about effectiveness or safety. Use the cost worksheet to compare written quotes on equal terms, then bring product-specific clinical questions to a qualified healthcare professional. Neither tool selects a treatment or a dose.
Sources
Educational editorial analysis by NAD Atlas. No firsthand treatment experience or clinical review is implied.